Latest Hotspot

Early data has been released by Inhibrx about INBRX-109's Phase 1 trial, focused on Ewing Sarcoma treatment

9 November 2023
3 min read

Inhibrx, Inc., a biopharmaceutical firm in the clinical stage that focuses on formulating treatments for cancer and rare conditions, declared the initial results concerning efficacy and safety from the Phase 1 trial. This trial was for INBRX-109, used in conjunction with Irinotecan and Temozolomide, designed for treating advanced or metastatic, non-removable Ewing sarcoma.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Out of the 13 assessable patients including 7 with classical Ewing sarcoma and 6 with round cell sarcoma, a disease control rate of 76.9% was recorded, signifying 10 out of 13 patients, as evaluated by RECISTv1.1. A durable clinical advantage was noted in 4 people (30.8%) who demonstrated disease control for more than 6 months. As of September 8, 2023, the longest period of steady disease was over 10 months and ongoing and 7 of the 13 remained part of the study.

INBRX-109 is a tetravalent death receptor 5 (DR5) agonist antibody which has been precision-engineered to leverage the tumor-inclined cell death brought about by DR5 activation. Overall, the combination of INBRX-109 with IRI/TMZ was well tolerated. Diarrhea, nausea, and fatigue were the most frequent unfavorable events, all aligning with the known safety characteristics of IRI/TMZ. No liver-related incidents of grade 3 or superior occurred.

"I am optimistic about the preliminary data in relapsed/refractory Ewing sarcoma patients. This group of patients have a high unfulfilled need and limited efficient therapy options," expressed Dr. Rashmi Chugh, MD, a Professor of Internal Medicine at the Division of Hematology/Oncology at the University of Michigan Rogel Comprehensive Cancer Center. "I anticipate the continued recruitment in this group of patients and am eager to see the outcomes of the enlargement."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 9, 2023, there are 33 investigational drugs for the DR5 target, including 48 indications, 51 R&D institutions involved, with related clinical trials reaching 55, and as many as 4368 patents.

In June 2021, Inhibrx initiated a randomized, blinded, placebo-controlled, registration-enabling Phase 2 trial of INBRX-109 in conventional chondrosarcoma, which is currently ongoing. In January 2021, the FDA granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma and orphan-drug designation to INBRX-109 for chondrosarcoma in the United States.

图形用户界面, 文本, 应用程序

描述已自动生成

Biological Glossary | What is Motif?
Bio Sequence
2 min read
Biological Glossary | What is Motif?
9 November 2023
Motifs in biology refer to nucleotide or amino-acid sequence patterns that are prevalent and usually associated with the biological function of a macromolecule.
Read →
Biological Glossary | What is Chemical Modification?
Bio Sequence
2 min read
Biological Glossary | What is Chemical Modification?
9 November 2023
Chemical modifications in biology refer to the changes in biomolecular structure and function brought about by the addition or removal of modifying elements.
Read →
IDRx shares initial findings from its ongoing Phase 1 StrateGIST trial at CTOS 2023, illustrating the promise of IDRX-42 for GIST patients
Latest Hotspot
3 min read
IDRx shares initial findings from its ongoing Phase 1 StrateGIST trial at CTOS 2023, illustrating the promise of IDRX-42 for GIST patients
9 November 2023
IDRx, Inc. has reported initial clinical results from its ongoing Phase 1 StrateGIST trial of IDRX-42. This trial is for patients with metastatic and/or inoperable gastrointestinal stromal tumors who have previously received at least one tyrosine kinase inhibitor therapy regime, now testing a higher dosage.
Read →
Research, Patent, and Literature Data behind the Early ADC Drug ORM-6151 Purchased by Bristol-Myers Squibb at a Huge Cost
Bio Sequence
3 min read
Research, Patent, and Literature Data behind the Early ADC Drug ORM-6151 Purchased by Bristol-Myers Squibb at a Huge Cost
9 November 2023
ORM-6151 is a monoclonal antibody drug that targets CD33 and GSPT1, developed by Orum Therapeutics.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.